Abstract 2749
Background
Optimal sequencing of new androgen-receptor targeted agents (ART) abiraterone and enzalutamide with docetaxel (D) and cabazitaxel (C) is unknown. In this large retrospective cohort of mCRPC patients, we evaluated the impact of 3 different sequences: D -> C-> ART (group 1), or D -> ART -> C (group 2), or ART -> D -> C (group 3)
Methods
Records of 560 consecutive mCRPC patients were retrospectively collected in 31 centres in 7 European countries from Jan 2011 to Jan 2016. Disease history and clinical characteristics at initiation of each therapy were collected. PSA response ≥ 50%, radiological or clinical progression-free survival (PFS) and overall survival (OS) with each treatment sequence were evaluated.
Results
At sequence initiation, patient characteristics were similar between the 3 sequences: median age was 67 years, 95% were ECOG 0-1, 59% had high disease volume, 42.6% had pain and 8% had visceral metastases. Median number of D cycles was 6 in the 3 groups. Median numbers of C cycles were 7, 6 and 5 in groups 1, 2 and 3 respectively. Median duration of follow-up was 33.7, 31.1, and 23.7 months in groups 1, 2 and 3. Main results are provided in the table.
| Sequence | PSA response ≥50% / Radiological or clinical PFS* | OS from Treatment 1* | ||
|---|---|---|---|---|
| Treatment 1 | Treatment 2 | Treatment 3 | ||
| D- > C- > ART (n = 129) | 61% / 11.5 | 61% / 11.0 | 37% / 12.4 | 37.3 [32.4; 45.2] |
| D- > ART- > C (n = 390) | 63% / 11.9 | 39% / 9.0 | 38% / 11.3 | 36.0 [33.4; 39.7] |
| ART- > D- > C (n = 41) | 60% / 7.4 | 42% / 6.9 | 31% / 8.9 | 30.1 [24.3; 52.7] |
| p value | 0.92 / ConclusionsPSA responses were generally similar for each treatment line in the 3 groups. No significant difference in OS was observed between the 3 sequences in this retrospective cohort. D showed a longer radiological or clinical PFS when given in first line. The activity of C was not influenced by ART. Sequencing should be based on individual disease characteristics and patients' status and preference. Clinical trial identificationLegal entity responsible for the studySponsor ARTIC FundingSanofi and Janssen DisclosureA. Angelergues: Consulting fee Sanofi Travel for meeting Astellas and Janssen. O. Caffo: Speakers bureaus: Astellas, Janssen, Sanofi, Bayer. S. Le Moulec: Nonremunerative positions of influence (eg, officer, board member, trustee, or public spokesperson): Sanofi, Roche, BMS, Merck. A. Guillot: Board Pfizer. D. Spaeth: Consulting fees (or other payment): Sanofi and Janssen. P. Beuzeboc: Consulting fees (or pther payment): Sanofi, Astellas, Janssen, Bayer, Amgen. J-C. Eymard: Consulting fees : Sanofi, Novartis, Pfizer, Janssen Astellas. A. Flechon: Consulting fees (or other payment): Sanofi, Astellas, Ipsen, Janssen, Ferring, Bayer. J. Alexandre: Consulting fees (or other payment): Roche, Pharmamar, Novartis. S. Oudard: Consulting fees (or other payment): Sanofi, Bayer, Astellas, Janssen. All other authors have declared no conflicts of interest. Resources from the same session3713 - ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)Presenter: Bijal Shah Session: Poster display Resources: Abstract 3305 - ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)Presenter: Michael Wang Session: Poster Display Resources: Abstract 3222 - ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL)Presenter: Sattva Neelapu Session: Poster Display Resources: Abstract 1560 - Younger age as a prognostic indicator in breast cancer: Correlation between clinical-pathologic factors and miRNAs and long-term follow-upPresenter: Maria Teresa Martinez Session: Poster display Resources: Abstract 2335 - Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)Presenter: Christy Toms Session: Poster display Resources: Abstract 3291 - Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts)Presenter: Géraldine Perkins Session: Poster display Resources: Abstract 3607 - What is the optimal annual interpretive volume for a radiologist reading screening mammograms?Presenter: Asli Uluturk Session: Poster display Resources: Abstract 1963 - What decides breast conservation versus mastectomy in the background of diverse sociocultural environment, an Indian studyPresenter: Poonamalle Padmanabhan Bapsy Session: Poster display Resources: Abstract 3503 - Waiting time to diagnosis and treatment of the head and neck cancer in four institutions in PortugalPresenter: Ana Castro Session: Poster display Resources: Abstract 1997 - Wait times for diagnosis and treatment of lung cancer: a single centre experiencePresenter: Catherine Labbe Session: Poster Display Resources: Abstract This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
| |||